Maze Therapeutics, Inc. Common Stock (MAZE) - Total Liabilities
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has total liabilities worth $78.50 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Maze Therapeutics, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Maze Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Maze Therapeutics, Inc. Common Stock (MAZE) total assets.
Maze Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norwegian Air Shuttle ASA
OL:NAS
|
Norway | Nkr38.28 Billion |
|
DOMS Industries Limited
NSE:DOMS
|
India | Rs4.21 Billion |
|
Rianlon Corp
SHE:300596
|
China | CN¥5.58 Billion |
|
Cansino Biologics Inc
SHG:688185
|
China | CN¥-4.93 Billion |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
USA | $2.02 Billion |
|
Fangda Special Steel Technology Co Ltd
SHG:600507
|
China | CN¥11.72 Billion |
|
Adecoagro SA
NYSE:AGRO
|
USA | $3.29 Billion |
|
Ujjivan Small Finance Bank Limited
NSE:UJJIVANSFB
|
India | Rs535.14 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Maze Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Maze Therapeutics, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maze Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Maze Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.16 Million | -3.38% |
| 2024-12-31 | $43.64 Million | -28.99% |
| 2023-12-31 | $61.45 Million | +26.66% |
| 2022-12-31 | $48.51 Million | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more